{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cell+and+Tissue-Based+Therapy", "query": { "condition": "Cell and Tissue-Based Therapy" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 87, "total_pages": 9, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cell+and+Tissue-Based+Therapy&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-06-26T20:14:15.804Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00688090", "title": "Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Melanoma", "Stage III and IV Melanoma" ], "interventions": [ { "name": "Biological: MKC1106-MT", "type": "BIOLOGICAL" }, { "name": "Biological: MKCC1106-MT", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Mannkind Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 19, "start_date": "2008-06", "completion_date": "2010-05", "has_results": false, "last_update_posted_date": "2010-08-03", "last_synced_at": "2026-06-26T20:14:15.804Z", "location_count": 2, "location_summary": "Los Angeles, California • Tampa, Florida", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00688090" }, { "nct_id": "NCT02188719", "title": "Donor-Alloantigen-Reactive Regulatory T Cell (darTregs) in Liver Transplantation", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Liver Transplantation" ], "interventions": [ { "name": "Anti-Thymocyte Globulin - Rabbit", "type": "BIOLOGICAL" }, { "name": "darTreg Infusion", "type": "BIOLOGICAL" }, { "name": "Everolimus", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Mycophenolate mofetil", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Acetaminophen", "type": "DRUG" }, { "name": "Diphenhydramine", "type": "DRUG" }, { "name": "Anti-Infective Prophylaxis", "type": "DRUG" }, { "name": "Leukapheresis", "type": "PROCEDURE" }, { "name": "Blood draws", "type": "PROCEDURE" }, { "name": "Liver biopsies", "type": "PROCEDURE" }, { "name": "Liver transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "21 Years to 70 Years" }, "enrollment_count": 15, "start_date": "2014-12-17", "completion_date": "2019-06-18", "has_results": true, "last_update_posted_date": "2020-09-22", "last_synced_at": "2026-06-26T20:14:15.804Z", "location_count": 3, "location_summary": "San Francisco, California • Chicago, Illinois • Rochester, Minnesota", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT02188719" }, { "nct_id": "NCT04093323", "title": "Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HLA-A2 Positive Cells Present", "Refractory Melanoma" ], "interventions": [ { "name": "Alpha-type-1 Polarized Dendritic Cells", "type": "BIOLOGICAL" }, { "name": "Celecoxib", "type": "DRUG" }, { "name": "PD-1 Ligand Inhibitor", "type": "DRUG" }, { "name": "PD1 Inhibitor", "type": "DRUG" }, { "name": "Recombinant Interferon Alfa-2b", "type": "BIOLOGICAL" }, { "name": "Rintatolimod", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2024-11-13", "completion_date": "2025-06-19", "has_results": true, "last_update_posted_date": "2026-02-25", "last_synced_at": "2026-06-26T20:14:15.804Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04093323" }, { "nct_id": "NCT04528680", "title": "Ultrasound-based Blood-brain Barrier Opening and Albumin-bound Paclitaxel and Carboplatin for Recurrent Glioblastoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Glioblastoma", "Gliosarcoma", "GBM", "Glioblastoma Multiforme", "Glioblastoma, IDH-wildtype", "Recurrent Glioblastoma" ], "interventions": [ { "name": "Sonication for opening of blood-brain barrier", "type": "DEVICE" }, { "name": "Chemotherapy, albumin-bound paclitaxel", "type": "DRUG" }, { "name": "Chemotherapy, carboplatin", "type": "DRUG" } ], "intervention_types": [ "DEVICE", "DRUG" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 57, "start_date": "2020-10-29", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-04-13", "last_synced_at": "2026-06-26T20:14:15.804Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT04528680" }, { "nct_id": "NCT00750009", "title": "Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Brain and Central Nervous System Tumors", "Chronic Myeloproliferative Disorders", "Leukemia", "Lymphoma", "Lymphoproliferative Disorder", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Neoplasms", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "educational intervention", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Case Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 583, "start_date": "2008-04", "completion_date": "2012-12", "has_results": false, "last_update_posted_date": "2020-07-27", "last_synced_at": "2026-06-26T20:14:15.804Z", "location_count": 4, "location_summary": "Detroit, Michigan • Cleveland, Ohio • Philadelphia, Pennsylvania", "locations": [ { "city": "Detroit", "state": "Michigan" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00750009" }, { "nct_id": "NCT04750954", "title": "Testing the Addition of An Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Pancreatic Neuroendocrine Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neuroendocrine Neoplasm" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Lutetium Lu 177 Dotatate", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Peposertib", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 29, "start_date": "2021-07-22", "completion_date": "2026-12-30", "has_results": false, "last_update_posted_date": "2026-06-15", "last_synced_at": "2026-06-26T20:14:15.804Z", "location_count": 5, "location_summary": "Duarte, California • Miami, Florida • Lexington, Kentucky + 2 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Lexington", "state": "Kentucky" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT04750954" }, { "nct_id": "NCT00448357", "title": "Allogeneic Hematopoietic Cell Transplantation for Patients With Busulfex-based Regimen", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Chronic Myeloproliferative Disorders", "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes" ], "interventions": [ { "name": "rabbit anti-thymocyte globulin (ATG)", "type": "BIOLOGICAL" }, { "name": "therapeutic allogeneic lymphocytes", "type": "BIOLOGICAL" }, { "name": "busulfan", "type": "DRUG" }, { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "tacrolimus", "type": "DRUG" }, { "name": "allogeneic hematopoietic stem cell transplantation", "type": "PROCEDURE" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" }, { "name": "methotrexate", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "UNC Lineberger Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 54, "start_date": "2005-10", "completion_date": "2015-11", "has_results": true, "last_update_posted_date": "2017-07-17", "last_synced_at": "2026-06-26T20:14:15.804Z", "location_count": 1, "location_summary": "Chapel Hill, North Carolina", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00448357" }, { "nct_id": "NCT00791037", "title": "Vaccine Therapy in Treating Patients With Stage IV Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "HER2-positive Breast Cancer", "Male Breast Cancer", "Recurrent Breast Cancer", "Stage IV Breast Cancer" ], "interventions": [ { "name": "HER-2/neu peptide vaccine", "type": "BIOLOGICAL" }, { "name": "leukapheresis", "type": "PROCEDURE" }, { "name": "ex vivo-expanded HER2-specific T cells", "type": "BIOLOGICAL" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "sargramostim", "type": "BIOLOGICAL" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE", "DRUG", "OTHER" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 23, "start_date": "2008-10", "completion_date": "2014-12", "has_results": true, "last_update_posted_date": "2017-05-25", "last_synced_at": "2026-06-26T20:14:15.804Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00791037" }, { "nct_id": "NCT06683378", "title": "A Study to Evaluate Feasibility, Safety, and Clinical Responses of Implanting Autologous Peripheral Nerve Tissue Into the Brain for Non-motor or Motor Symptoms in Patients With Parkinson's Disease Undergoing DBS Surgery", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Parkinson's Disease" ], "interventions": [ { "name": "Reparative Autologous peripheral nerve tissue", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Craig van Horne, MD, PhD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "45 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "45 Years to 75 Years" }, "enrollment_count": 24, "start_date": "2025-07-21", "completion_date": "2028-02-28", "has_results": false, "last_update_posted_date": "2025-08-14", "last_synced_at": "2026-06-26T20:14:15.804Z", "location_count": 1, "location_summary": "Lexington, Kentucky", "locations": [ { "city": "Lexington", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT06683378" }, { "nct_id": "NCT03186417", "title": "Mesenchymal Stem Cells in Early Rheumatoid Arthritis", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "2 million hMSC/kg", "type": "BIOLOGICAL" }, { "name": "4 million hMSC/kg", "type": "BIOLOGICAL" }, { "name": "6 million hMSC/kg", "type": "BIOLOGICAL" }, { "name": "placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "MetroHealth Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 10, "start_date": "2017-12-15", "completion_date": "2023-05-31", "has_results": false, "last_update_posted_date": "2023-06-23", "last_synced_at": "2026-06-26T20:14:15.804Z", "location_count": 2, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT03186417" } ] }